These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38347264)

  • 21. ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.
    Li L; Gong Y; Tang J; Yan C; Li L; Peng W; Cheng Z; Yu R; Xiang Q; Deng C; Mu J; Xia J; Luo X; Wu Y; Xiang T
    Cell Mol Life Sci; 2022 Jan; 79(2):83. PubMed ID: 35048182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Prolyl 4-Hydroxylase Subunit Alpha 3 Expression as an Independent Prognostic Biomarker and Correlated With Immune Infiltration in Gastric Cancer.
    Niu X; Ren L; Wang S; Gao D; Ma M; Hu A; Qi H; Zhang S
    Front Genet; 2022; 13():952335. PubMed ID: 35846138
    [No Abstract]   [Full Text] [Related]  

  • 23. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression.
    Lin CY; Tsai CL; Chao A; Lee LY; Chen WC; Tang YH; Chao AS; Lai CH
    J Mol Med (Berl); 2021 Aug; 99(8):1125-1137. PubMed ID: 33954835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
    Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
    Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The CD47-SIRPα axis is a promising target for cancer immunotherapies.
    Hao Y; Zhou X; Li Y; Li B; Cheng L
    Int Immunopharmacol; 2023 Jul; 120():110255. PubMed ID: 37187126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
    Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proinflammatory polarization strongly reduces human macrophage in vitro phagocytosis of tumor cells in response to CD47 blockade.
    Antonsen KW; Jensen AG; Carstensen M; Nejsum LN; Sorensen BS; Etzerodt A; Moestrup SK; Møller HJ
    Eur J Immunol; 2024 Jul; 54(7):e2350824. PubMed ID: 38593339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated Analysis of Phagocytic and Immunomodulatory Markers in Cervical Cancer Reveals Constellations of Potential Prognostic Relevance.
    Yordanov A; Damyanova P; Vasileva-Slaveva M; Hasan I; Kostov S; Shivarov V
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
    Wang T; Wang YX; Dong YQ; Yu YL; Ma K
    Arch Oral Biol; 2020 May; 113():104711. PubMed ID: 32220804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy.
    Li Y; Yi J; Ma R; Wang Y; Lou X; Dong Y; Cao Y; Li X; Wang M; Dang X; Li R; Lei N; Song H; Qin Z; Yang W
    J Control Release; 2024 Sep; 373():447-462. PubMed ID: 39038546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy.
    Zhu H; Leiss L; Yang N; Rygh CB; Mitra SS; Cheshier SH; Weissman IL; Huang B; Miletic H; Bjerkvig R; Enger PØ; Li X; Wang J
    Oncotarget; 2017 Feb; 8(7):12145-12157. PubMed ID: 28076333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD47-mediated immune evasion in early-stage lung cancer progression.
    Chuang CH; Zhen YY; Ma JY; Lee TH; Hung HY; Wu CC; Wang PH; Huang CT; Huang MS; Hsiao M; Lee YR; Huang CF; Chang YC; Yang CJ
    Biochem Biophys Res Commun; 2024 Aug; 720():150066. PubMed ID: 38749193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells.
    Bian Z; Shi L; Guo YL; Lv Z; Tang C; Niu S; Tremblay A; Venkataramani M; Culpepper C; Li L; Zhou Z; Mansour A; Zhang Y; Gewirtz A; Kidder K; Zen K; Liu Y
    Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5434-43. PubMed ID: 27578867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value and Immunological Role of P4HA3 in Colon Adenocarcinoma.
    Huang J; Zhao P; Shi J; Ning J; Wang Z; Luo Y; Qin J; Huang X
    Int J Gen Med; 2023; 16():1953-1971. PubMed ID: 37251280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
    Weiskopf K; Jahchan NS; Schnorr PJ; Cristea S; Ring AM; Maute RL; Volkmer AK; Volkmer JP; Liu J; Lim JS; Yang D; Seitz G; Nguyen T; Wu D; Jude K; Guerston H; Barkal A; Trapani F; George J; Poirier JT; Gardner EE; Miles LA; de Stanchina E; Lofgren SM; Vogel H; Winslow MM; Dive C; Thomas RK; Rudin CM; van de Rijn M; Majeti R; Garcia KC; Weissman IL; Sage J
    J Clin Invest; 2016 Jul; 126(7):2610-20. PubMed ID: 27294525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
    Hu LY; Zhuang WT; Chen MJ; Liao J; Wu DF; Zhang YX; Pang LL; Huang YH; Mao TQ; Yang MJ; Peng PJ; Liang JX; Chen L; Zeng LJ; Zhang L; Fang WF
    J Thorac Oncol; 2024 Aug; 19(8):1186-1200. PubMed ID: 38553005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Latest Findings on the Role of CD47 in Tumor Immune Evasion and Related Targeted Therapies].
    Jie XL; Kong YY; Zhou GB
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):455-461. PubMed ID: 37248568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.